TACT Pivotal Clinical Trial of TULSA-PRO®: All Primary Efficacy and Safety Endpoints, and Key Secondary Endpoints Achieved

TACT Pivotal Clinical Trial of TULSA-PRO®
All Primary Efficacy and Safety Endpoints, and Key Secondary Endpoints Achieved

We are pleased to announce the top line results of our Pivotal Clinical trial TACT that was designed to support Profound’s application to the U.S Food and Drug Administration for 510(k) clearance to market TULSA-PRO® in the United States.

To help put the TACT data in the appropriate context we have created an accompanying presentation.

TACT Data and the accompanying TACT Data Presentation are now live on our Investor Page

The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.